GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)), Ideaya Biosciences ((IDYA)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER). The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or with a PD-1 inhibitor, in treating aggressive solid tumors with specific genetic traits.
The intervention involves the drug GSK4418959, tested both as a monotherapy and in combination with a PD-1 inhibitor. The goal is to assess its ability to reduce tumor size and its safety profile.
This interventional study is non-randomized and sequential, focusing on treatment as its primary purpose. It is open-label, meaning no masking is involved, allowing both participants and researchers to know the treatment being administered.
The study began on December 13, 2024, with the last update on August 5, 2025. These dates mark the study’s progress and updates, crucial for tracking its development and potential outcomes.
The study’s progress could influence GSK and Ideaya Biosciences’ stock performance, as positive results might boost investor confidence and market value. The competitive landscape in oncology could also be affected, depending on the study’s outcomes.
The study is ongoing, with further details available on the ClinicalTrials portal.